Chinese vaccine shows promise in stopping plaque build-up in arteries
heart disease , which is the leading cause of death worldwide.
Advertisement
The team said the experimental vaccine had shown promise in a trial on mice.
It targets a condition known as atherosclerosis that causes a build-up of plaque – a deposit of fatty substances, cholesterol and cellular waste – in the arteries, which can lead to blood clots, stroke and heart attacks.
The nanovaccine was developed by a team of researchers from institutes including the Nanjing University of Science and Technology and the University of Science and Technology of China.
To create it, the team attached either an antigen that triggers an immune response against atherosclerosis or an immune response booster onto tiny iron oxide nanoparticles.
Advertisement
When the resulting nanovaccine was injected into mice that were fed a high-cholesterol diet, the team found that the immune response triggered was able to reduce the development of atherosclerosis.
'Our findings demonstrate that the two-pronged nanovaccine delivery strategy is effective against atherosclerosis,' the team said in a paper published in the peer-reviewed journal Nature Communications on March 2.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
15 hours ago
- South China Morning Post
China's Tsinghua University helps to break 40-year-old maths cap on computer speed
Chinese computer scientists have solved a 40-year-old mathematics bottleneck, a breakthrough that holds significant implications for boosting the performance of hi-tech areas ranging from chip design and telecommunications to drone navigation One of the most fundamental problems in theoretical computer science is finding the shortest or most efficient path from one starting point to every other point in a network. Within the academic community, this problem is known as the 'single-source shortest-paths' problem (SSSP). For decades, the most famous and reliable method to overcome this has been Dijkstra's algorithm, which repeatedly searches for the shortest path for each segment, continuously comparing and sorting the points until reaching its destination. Yet this sorting step poses an unavoidable speed limit. A new approach devised by a group of young Chinese scientists promises to overcome the barrier, by skipping the sorting process and focusing only on the shortest distance between the most important points, thus greatly reducing calculation time. The study, led by associate professor Duan Ran's research team at the Institute for Interdisciplinary Information Sciences (IIIS) at Tsinghua University, was published last month on arXiv, an open-access platform for preprint papers that are yet to be peer reviewed. This development also won the Best Paper Award at the ACM Symposium on Theory of Computing or STOC, held in Prague in June.
South China Morning Post
a day ago
- South China Morning Post
How Chinese team's fast DNA blood test could transform pancreatic cancer detection
A genomic tool developed by researchers in China could transform early detection and personalised treatment for pancreatic cancer – one of the deadliest forms of the disease. Known as the 'king of cancers', pancreatic cancer is characterised by late diagnosis, rapid metastasis and limited treatment targets. It ranks as the sixth leading cause of global cancer mortality, according to the Global Cancer Observatory. However, the 'Uni-C' single-cell 'multiomics' technology developed by the Chinese team could enable entire DNA analysis in less than a day, matching the accuracy of traditional biopsies and promising more early detection. Lin Da, professor at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CAS), and Yang Yuqin, director of the Laboratory Animal Centre at Shanghai General Hospital, led the team, which introduced Uni-C in a study published in Nature Communications on July 26. The pathbreaking method can simultaneously decode three critical layers of genomic information from individual circulating tumour cells (CTCs) – large-scale structural variations, small-scale mutations, and 3D chromatin architecture – providing unprecedented insights for early screening, monitoring, and tailored immunotherapy. CTCs are rare 'seeds' shed from tumours into the bloodstream, carrying the complete genomic profile of the primary tumour. Yet their scarcity – often just a few cells per millilitre (0.03 ounce) of blood – has made comprehensive analysis nearly impossible.
South China Morning Post
2 days ago
- South China Morning Post
When experimental treatments lead to death in Hong Kong, prosecution is not always simple
The medical profession is one of the pillars of Hong Kong society and its doctors, as well as other professionals, are expected to, and often do, uphold the highest standards of professional conduct. But a dark corner of the healthcare industry exists in the grey area between medical treatment and experimental procedure. Over the years there have been a number of tragic cases where the administering of experimental treatments has led to the patient's death. As with medical negligence more generally, conduct of this character is prosecuted under the crime of gross negligence manslaughter, which remains a common law offence. In fact, developments in this area of the Hong Kong common law have often come from the medical sector, with the leading case on gross negligence manslaughter being the prosecution of Dr Mak Wan-ling, which led to a decision in 2019 from the Court of Final Appeal that clarified the elements of the offence. Questions were also raised in that series of cases about the legal relationship of the companies running the clinic (also known as the 'DR Group') and whether that was relevant to the law of gross negligence manslaughter. Indeed, these cases may often serve to shine a spotlight on areas where more regulation is required. To clarify the legal responsibilities of other forms of health treatment centres, the government enacted the Private Healthcare Facilities Ordinance (Cap 633) in 2018, which now imposes a number of legal duties on persons who operate private healthcare facilities, clinics and so on.
